Name | Sponsor | Class | Target | Indication | Major mechanism | Current status |
---|---|---|---|---|---|---|
Elotuzumab | BMS/Abbott | Humanized IgG1 | CS1 | Multiple Myeloma | ADCC12,16 | Phase II/III |
Farletuzumab | Morphotek | Humanized IgG1 | Folate Receptor α | Ovarian Cancer | Phase III | |
Inotuzumab ozogamicin | Pfizer/UCB | Humanized IgG4 | CD22 | Acute Lymphocytic Leukemia/ Non-Hodgkin’s Lymphoma | ADC | Phase III |
Moxetumomab pasudotox | AstraZeneca | Murine Fv | CD22 | Hairy Cell Leukemia | Immunotoxin | Phase III |
Naptumomab estafenatox | Active Biotech | Murine Fab | 5T4 | Renal Cell Carcinoma | Immunoconjugate | |
Necitumumab | ImClone Systems | Human IgG1 | EGFR | Non-Small Cell Lung Cancer | Phase III | |
Nivolumab | BMS | Human IgG4 | PD1 | Non-Small Cell Lung Cancer/ Renal Cell Carcinoma/Melanoma | Signal Inhibition | Phase III |
Onartuzumab | Genentech | Humanized IgG1 | c-Met | Non-Small Cell Lung Cancer/ Gastric Cancer | Signal Inhibition | |
Racotumomab | CIMAB | Murine | GM3 | Non-Small Cell Lung Cancer | Active Immunization (Vaccine) | Phase III |
Rilotumumab | Amgen | Human IgG2 | HGF/SF | Gastric/Gastresophageal Junction Adenocarinoma | Signal Inhibition | Phase III |